Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0000492

Oxycodone hydrochloride

European Pharmacopoeia (EP) Reference Standard

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C18H21NO4 · HCl
Numéro CAS:
124-90-3
Poids moléculaire :
351.82
Numéro MDL:
MFCD00137583
Code UNSPSC :
41116107
ID de substance PubChem :
329830982
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

oxycodone

Fabricant/nom de marque

EDQM

Contrôle du médicament

USDEA Schedule I; regulated under CDSA - not available from Sigma-Aldrich Canada; estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

Cl.[H][C@@]12Oc3c(OC)ccc4C[C@H]5N(C)CC[C@@]1(c34)[C@@]5(O)CCC2=O

InChI

1S/C18H21NO4.ClH/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;/h3-4,13,16,21H,5-9H2,1-2H3;1H/t13-,16+,17+,18-;/m1./s1

Clé InChI

MUZQPDBAOYKNLO-RKXJKUSZSA-N

Informations sur le gène

human ... OPRM1(4988)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Oxycodone hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

μ and κ opioid receptor agonist.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0000453

Oxycodone impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000723

Thebaine, European Pharmacopoeia (EP) Reference Standard

1485191

Oxycodone, United States Pharmacopeia (USP) Reference Standard

1485216

Oxycodone Related Compound A, United States Pharmacopeia (USP) Reference Standard

1485205

Oxycodone hydrochloride, United States Pharmacopeia (USP) Reference Standard

1485238

Oxycodone Related Compound C, United States Pharmacopeia (USP) Reference Standard

1485227

Oxycodone Related Compound B, United States Pharmacopeia (USP) Reference Standard

BP1068

Oxycodone hydrochloride, British Pharmacopoeia (BP) Reference Standard

BP1136

Oxycodone impurity standard, British Pharmacopoeia (BP) Reference Standard

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302,H336

Classification des risques

Acute Tox. 4 Oral - STOT SE 3

Organes cibles

Central nervous system

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Salvatore V Colucci et al.
Clinical drug investigation, 34(6), 421-429 (2014-04-24)
Abuse of opioid analgesics has become a public health issue. Some opioid abusers use intravenous administration to increase the magnitude of positive reinforcing effects. Intravenous co-administration of oxycodone with naloxone, an opioid antagonist, may reduce these rewarding effects and discourage
Caitlin M Vander Weele et al.
The European journal of neuroscience, 40(7), 3041-3054 (2014-09-12)
While most drugs of abuse increase dopamine neurotransmission, rapid neurochemical measurements show that different drugs evoke distinct dopamine release patterns within the nucleus accumbens. Rapid changes in dopamine concentration following psychostimulant administration have been well studied; however, such changes have
Carrie L Wade et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(2), 421-428 (2014-07-26)
The abuse of prescription opioids that are used for the treatment of chronic pain is a major public health concern, costing ∼$53.4 billion annually in lost wages, health-care costs, and criminal costs. Although opioids remain a first-line therapy for the
Jason A Miranda et al.
PloS one, 9(8), e106108-e106108 (2014-08-27)
Sensory processing in the spinal cord during disease states can reveal mechanisms for novel treatments, yet very little is known about pain processing at this level in the most commonly used animal models of articular pain. Here we report a
Tomoe Kanbara et al.
Neuroscience letters, 580, 119-124 (2014-08-17)
It has begun to be understood that μ-opioid receptor (MOR) produces ligand-biased agonism, which contributes to differential physiological functions of MOR agonists. We previously demonstrated that in oxaliplatin-induced neuropathy in rats, morphine and oxycodone exhibited antinociceptive effects while antinociception of
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique